1.
Schadendorf D, Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Mortier L, Robert C, Schachter J, Ortmann C-E, de Jong E, Gasal E, Kefford R, Kirkwood JM, Long GV. Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. J of Skin [Internet]. 2019Nov.9 [cited 2020Nov.27];30:S53. Available from: https://jofskin.org/index.php/skin/article/view/781